JPS60500862A - 抗マラリア原虫保護抗体を誘導するポリペプチド分画とそれを含む免疫原性組成物 - Google Patents
抗マラリア原虫保護抗体を誘導するポリペプチド分画とそれを含む免疫原性組成物Info
- Publication number
- JPS60500862A JPS60500862A JP59500519A JP50051984A JPS60500862A JP S60500862 A JPS60500862 A JP S60500862A JP 59500519 A JP59500519 A JP 59500519A JP 50051984 A JP50051984 A JP 50051984A JP S60500862 A JPS60500862 A JP S60500862A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- molecular weight
- antibodies
- plasmodium
- polypeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 110
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 99
- 229920001184 polypeptide Polymers 0.000 title claims description 91
- 244000045947 parasite Species 0.000 title claims description 76
- 230000001681 protective effect Effects 0.000 title claims description 52
- 239000000203 mixture Substances 0.000 title claims description 33
- 230000002163 immunogen Effects 0.000 title claims description 28
- 239000003430 antimalarial agent Substances 0.000 title claims description 9
- 230000000078 anti-malarial effect Effects 0.000 title claims description 8
- 241001465754 Metazoa Species 0.000 claims description 70
- 241000282693 Cercopithecidae Species 0.000 claims description 47
- 241000224016 Plasmodium Species 0.000 claims description 44
- 210000002966 serum Anatomy 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 36
- 239000000427 antigen Substances 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 201000004792 malaria Diseases 0.000 claims description 23
- 208000015181 infectious disease Diseases 0.000 claims description 22
- 108060003951 Immunoglobulin Proteins 0.000 claims description 21
- 102000018358 immunoglobulin Human genes 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 20
- 235000018102 proteins Nutrition 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 241000282412 Homo Species 0.000 claims description 16
- 210000004408 hybridoma Anatomy 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 229960005486 vaccine Drugs 0.000 claims description 14
- 241000699670 Mus sp. Species 0.000 claims description 11
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 11
- 238000001962 electrophoresis Methods 0.000 claims description 11
- 230000002458 infectious effect Effects 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 241000894007 species Species 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 241000223960 Plasmodium falciparum Species 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 235000004252 protein component Nutrition 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 230000001747 exhibiting effect Effects 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- 238000002835 absorbance Methods 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000012459 cleaning agent Substances 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000001568 sexual effect Effects 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 230000005847 immunogenicity Effects 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 238000000354 decomposition reaction Methods 0.000 claims 2
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 238000002523 gelfiltration Methods 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 description 12
- 230000003053 immunization Effects 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 206010003445 Ascites Diseases 0.000 description 10
- 230000003071 parasitic effect Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 241000282695 Saimiri Species 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 241000288906 Primates Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 230000024241 parasitism Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000019687 Lamb Nutrition 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000003505 Myosin Human genes 0.000 description 3
- 108060008487 Myosin Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003936 merozoite Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 238000006165 Knowles reaction Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
- 101710197241 Accessory gland-specific peptide 70A Proteins 0.000 description 1
- 241000282708 Aotus <primate> Species 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101000693916 Gallus gallus Albumin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 238000003508 chemical denaturation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 230000000282 effect on parasite Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010039 intracellular degradation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 239000011022 opal Substances 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 230000003108 parasitologic effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000000606 pro-mitotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8221817A FR2538252B3 (fr) | 1982-12-27 | 1982-12-27 | Fraction polypeptidique de poids moleculaire moyen 100 000 inductrice d'anticorps protecteurs contre des parasites du paludisme et compositions immunogenes les contenant |
| FR8221817 | 1982-12-27 | ||
| FR8221818 | 1982-12-27 | ||
| FR8312496 | 1983-07-28 | ||
| FR8320510 | 1983-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS60500862A true JPS60500862A (ja) | 1985-06-06 |
Family
ID=9280527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59500519A Pending JPS60500862A (ja) | 1982-12-27 | 1983-12-27 | 抗マラリア原虫保護抗体を誘導するポリペプチド分画とそれを含む免疫原性組成物 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS60500862A (fr) |
| FR (1) | FR2538252B3 (fr) |
-
1982
- 1982-12-27 FR FR8221817A patent/FR2538252B3/fr not_active Expired
-
1983
- 1983-12-27 JP JP59500519A patent/JPS60500862A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FR2538252A1 (fr) | 1984-06-29 |
| FR2538252B3 (fr) | 1985-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kaushal et al. | Monoclonal antibodies against surface determinants on gametes of Plasmodium gallinaceum block transmission of malaria parasites to mosquitoes. | |
| TWI517858B (zh) | 經純化之瘧原蟲屬（Ｐｌａｓｍｏｄｉｕｍ）及疫苗組成物 | |
| US5231168A (en) | Malaria antigen | |
| DE69229107T2 (de) | Peptidsequenzen, spezifisch für die hepatitische phase von p. falciparum, epitope tragend; die die fähigkeit besitzen, die t-lymphozyten anzuregen | |
| JPH01502194A (ja) | 肝細胞内で亜三日熱マラリヤ原虫により生成されたタンパク質の特微的なエピトープを単数又は複数有する少なくとも１つのペプチド配列を含む分子、及びこれらの分子を含む化合物 | |
| US4596707A (en) | Babesia parasite antigen useful in vaccine and diagnostic reagent | |
| Cheong et al. | Immunogenicity of bacterial-expressed recombinant Plasmodium knowlesi merozoite surface protein-1 42 (MSP-1 42) | |
| KR910005702B1 (ko) | 말라리아 기생충에 대한 방어항체를 유도하는 폴리펩티드 단편을 함유한 면역원 조성물의 제조방법 | |
| US8211447B2 (en) | Recombinant P. falciparum merozoite protein-142 vaccine | |
| JPS6072827A (ja) | エイメリア種のメロゾイトに対して反応性の抗原およびモノクロナル抗体 | |
| US8716443B2 (en) | Sub-region of a plasmodium protein with improved vaccine potential, and medical uses thereof | |
| Gregoire et al. | Protective monoclonal antibodies from mice vaccinated or chronically infected with Schistosoma mansoni that recognize the same antigens. | |
| KR20020093000A (ko) | 말라리아원충 항원 폴리펩티드 에스이36, 그 정제방법,그리고 이것으로부터 얻어지는 항원을 이용하는 백신 및진단제 | |
| Charoenvit et al. | Active and passive immunization against Plasmodium yoelii sporozoites. | |
| Tamborrini et al. | The malaria blood stage antigen Pf CyRPA formulated with the TLR-4 agonist adjuvant GLA-SE elicits parasite growth inhibitory antibodies in experimental animals | |
| JP4991308B2 (ja) | 熱帯熱マラリア原虫（Ｐｌａｓｍｏｄｉｕｍｆａｌｃｉｐａｒｕｍ）のＬＳＡ−５肝臓期および血中期抗原、この抗原を含有する免疫原性組成物、およびマラリアに対するワクチン | |
| CN102643336A (zh) | 禽嗜鹦鹉热衣原体外膜蛋白N-PmpD及制备方法和应用 | |
| Mehrizi et al. | IgG subclasses pattern and high-avidity antibody to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in an unstable hypoendemic region in Iran | |
| JPS60500862A (ja) | 抗マラリア原虫保護抗体を誘導するポリペプチド分画とそれを含む免疫原性組成物 | |
| Dadley-Moore et al. | Synthetic peptide antigens induce antibodies to Taenia ovis oncospheres | |
| RU2661028C2 (ru) | Фармацевтическая композиция для пассивной иммунизации против бешенства, фармацевтический набор, способ применения фармацевтического набора | |
| Kawasaki et al. | Immune response of BALB/c mouse immunized with recombinant MSPs proteins of Anaplasma marginale binding to immunostimulant complex (ISCOM) | |
| Fruit et al. | Trypanosoma cruzi: location of a specific antigen on the surface of bloodstream trypomastigote and culture epimastigote forms | |
| Ahmad et al. | The role of adjuvant on safety and antibody modulation of dromedary camel | |
| US5229110A (en) | Process for preparing a vaccine against malaria |